US EditionPublished • loading... • Updated
FDA vaccines chief Vinay Prasad to step down in April
Vinay Prasad’s tenure as FDA’s biologics chief was marked by controversies over rare disease drug scrutiny and vaccine regulation, with multiple agency rejections and leadership disputes.
- The FDA confirmed Vinay Prasad, a top official overseeing vaccines and gene therapies, will depart in April and has not named a successor.
- On 2026-03-06, the Center for Biologics Evaluation and Research increased scrutiny and rejected at least five cell and gene therapies, with a recent high-profile rejection of a rare-blood-cancer drug, amid disputes with drugmakers, and the Health and Human Services Department criticized an experimental Huntington's treatment the day before.
- Sources describe management actions that reshaped CBER's internal operations, including firing staff and demanding calendar visibility from California, after a brief ouster and rehiring in July.
- Prasad's actions produced immediate regulatory consequences, including a White House-intervened review after he refused to review a Moderna flu vaccine, and control of vaccine surveillance shifted from career staff.
- Amid a broader shift under Health Secretary Robert F. Kennedy Jr., Prasad's exit signals wider policy implications as the FDA adopts a more vaccine-skeptical approach; this is a developing story STAT will update.
Insights by Ground AI
71 Articles
71 Articles
Trump's controversial vaccine chief ousted
The Trump administration’s head of vaccines will leave the U.S. Food and Drug Administration next month following a tenure marked by several high-profile controversies. Dr. Vinay Prasad, who leads the FDA’s Center for Biologics Evaluation and Research, will depart at the end of April, the Wall Stree...
·United States
Read Full Article
Coverage Details
Total News Sources71
Leaning Left13Leaning Right3Center50Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
L 20%
C 76%
Factuality
To view factuality data please Upgrade to Premium
